--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-227191" form_type: "8-K" ticker: "GMED" cik: "0001237831" company_name: "GLOBUS MEDICAL INC" filed_at: "2023-09-01T23:59:59+00:00" generated_at: "2026-06-11T00:22:35.938509+00:00" event_type: "m_and_a" sentiment: "positive" materiality_score: 0.75 calibrated_materiality_score: 0.75 confidence: "high" source: SEC EDGAR --- # Globus Medical completes merger with NuVasive; expands board, converts notes ## Summary - NuVasive shareholders received 0.75 Globus shares per share; NuVasive stock ceased trading Aug 31. - Globus Board expanded from 8 to 11; added NuVasive directors John DeFord, Leslie Norwalk, Daniel Wolterman. - NuVasive's $450M 0.375% convertible notes now convertible into Globus common at 8.0399 shares/$1,000 principal. - Globus guaranteed NuVasive's note obligations; also amended call/warrant options for Globus stock. - Combined company positioned as leading global musculoskeletal firm; financial benefits to be discussed in Q3 call. ## SEC filing metadata - accession: 0001193125-23-227191 - form_type: 8-K - ticker: GMED - cik: 0001237831 - company_name: GLOBUS MEDICAL INC - filed_at: 2023-09-01T23:59:59+00:00 - event_type: m_and_a - sentiment: positive - materiality_score: 0.75 - calibrated_materiality_score: 0.75 - confidence: high - sec_items: 1.01, 2.01, 2.03, 3.02, 5.02, 7.01, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000119312523227191/0001193125-23-227191-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000119312523227191/d479094d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-227191 - JSON: https://secwatch.observer/filing/0001193125-23-227191.json - Plain text: https://secwatch.observer/filing/0001193125-23-227191.txt ## Key facts - Debt Financings GLOBUS MEDICAL INC amended convertible notes of $450.0 million with Wilmington Trust, National Association at 0.375% per annum maturing March 15, 2025. - Instrument: convertible notes - Principal: $450.0 million - Counterparty: Wilmington Trust, National Association - Rate: 0.375% per annum - Maturity: March 15, 2025 - Event: amendment source text: 2, 2020 (the “Base Indenture” and, together with that certain First Supplemental Indenture, the “Indenture”), by and between NuVasive and the Trustee, relating to NuVasive’s $450.0 million in aggregate principal amount of 0.375% Convertible Senior Notes due 2025 (the “Notes”). As a result of the Merger, and pursuant to the First Supplemental Indenture, the Notes evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000119312523227191/0001193125-23-227191-index.htm - Executive change Leslie V. Norwalk was appointed as Director at GLOBUS MEDICAL INC. - Action: appointed - Role: Director source text: on September 1, 2023, the board of directors of Globus (the “Globus Board”) elected and designated Leslie V. Norwalk, John A. DeFord, and Daniel J. Wolterman (collectively, the “New Directors”), who were previously members of the board of directors of NuVasive, to serve on the Globus Board effective immediately after the consummation of the Merger. evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000119312523227191/0001193125-23-227191-index.htm - Executive change Daniel J. Wolterman was appointed as Director at GLOBUS MEDICAL INC. - Action: appointed - Role: Director source text: on September 1, 2023, the board of directors of Globus (the “Globus Board”) elected and designated Leslie V. Norwalk, John A. DeFord, and Daniel J. Wolterman (collectively, the “New Directors”), who were previously members of the board of directors of NuVasive, to serve on the Globus Board effective immediately after the consummation of the Merger. evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000119312523227191/0001193125-23-227191-index.htm - Executive change John A. DeFord was appointed as Director at GLOBUS MEDICAL INC. - Action: appointed - Role: Director source text: on September 1, 2023, the board of directors of Globus (the “Globus Board”) elected and designated Leslie V. Norwalk, John A. DeFord, and Daniel J. Wolterman (collectively, the “New Directors”), who were previously members of the board of directors of NuVasive, to serve on the Globus Board effective immediately after the consummation of the Merger. evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000119312523227191/0001193125-23-227191-index.htm - M&A Transactions GLOBUS MEDICAL INC completed an acquisition involving NuVasive, Inc. for 0.75 shares of Globus Class A Common Stock (closed 2023-09-01). - Action: acquisition - Counterparty: NuVasive, Inc. - Consideration: 0.75 shares of Globus Class A Common Stock - Closing: 2023-09-01 source text: owned subsidiary of Globus. At the consummation of the Merger, each issued and outstanding share of common stock of NuVasive, $0.001 par value per share, was converted into 0.75 fully paid and non-assessable shares of Globus Class A Common Stock, and the right to receive cash in lieu of fractional shares. The issuance of Globus Class A Common Stock in evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000119312523227191/0001193125-23-227191-index.htm - Material Agreements GLOBUS MEDICAL INC entered into First Supplemental Indenture with Wilmington Trust, National Association valued at $450.0 million (effective 2023-09-01). - Action: entry - Agreement: notes offering - Counterparty: Wilmington Trust, National Association - Value: $450.0 million - Effective: 2023-09-01 source text: on September 1, 2023, Globus Medical, Inc., a Delaware corporation (“Globus”), NuVasive, Inc., a Delaware corporation (“NuVasive”), and Wilmington Trust, National Association, as trustee (the “Trustee”) entered into that certain First Supplemental Indenture (the “First Supplemental Indenture”) to the Indenture, dated as of March 2, 2020 (the “Base Indenture” and, together with that certain First Supplemental Indenture, the “Indenture”), by and between NuVasive and the Trustee, relating to NuVasive’s $450.0 million in aggregate principal amount of 0.375% Convertible Senior Notes due 2025 (the “Notes”). evidence_url: https://www.sec.gov/Archives/edgar/data/1237831/000119312523227191/0001193125-23-227191-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.